

Western Sky Community Care (Org ID: 3953239, SubID: 14650, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)
 Measurement Year - 2019

Audit Review Table				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and Screening				
Adult BMI Assessment (aba)		0.0%	NA	Small Denominator
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		62.3%	R	Reportable
<i>Counseling for Nutrition</i>		52.6%	R	Reportable
<i>Counseling for Physical Activity</i>		50.4%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		65.7%	R	Reportable
<i>IPV</i>		79.6%	R	Reportable
<i>MMR</i>		85.2%	R	Reportable
<i>HiB</i>		76.8%	R	Reportable
<i>Hepatitis B</i>		80.6%	R	Reportable
<i>VZV</i>		82.4%	R	Reportable
<i>Pneumococcal Conjugate</i>		65.7%	R	Reportable
<i>Hepatitis A</i>		80.6%	R	Reportable
<i>Rotavirus</i>		65.7%	R	Reportable
<i>Influenza</i>		34.3%	R	Reportable
<i>Combination #2</i>		63.0%	R	Reportable
<i>Combination #3</i>		58.3%	R	Reportable
<i>Combination #4</i>		56.5%	R	Reportable
<i>Combination #5</i>		51.9%	R	Reportable
<i>Combination #6</i>		25.0%	R	Reportable
<i>Combination #7</i>		50.0%	R	Reportable
<i>Combination #8</i>		25.0%	R	Reportable
<i>Combination #9</i>		24.1%	R	Reportable
<i>Combination #10</i>		24.1%	R	Reportable
Immunizations for Adolescents (ima)				
<i>Meningococcal</i>		84.8%	R	Reportable
<i>Tdap</i>		90.2%	R	Reportable
<i>HPV</i>		37.2%	R	Reportable
<i>Combination #1</i>		84.8%	R	Reportable
<i>Combination #2</i>		36.6%	R	Reportable
Lead Screening in Children (lsc)		39.5%	R	Reportable
Breast Cancer Screening (bcs)			NA	Small Denominator
Cervical Cancer Screening (ccs)		24.8%	R	Reportable
Chlamydia Screening in Women (chl)				
16-20 Years		50.1%	R	Reportable
21-24 Years		55.3%	R	Reportable
Total		52.5%	R	Reportable
Effectiveness of Care: Respiratory Conditions				
Appropriate Testing for Pharyngitis (cwp)	Y			
3-17 Years		74.4%	R	Reportable
18-64 Years		69.1%	R	Reportable
65+ Years			NA	Small Denominator
Total		72.8%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)			NA	Small Denominator
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		38.2%	R	Reportable
<i>Bronchodilator</i>		69.8%	R	Reportable
Medication Management for People With Asthma (mma)	Y			
5-11 Years: Medication Compliance 50%			NA	Small Denominator
5-11 Years: Medication Compliance 75%			NA	Small Denominator
12-18 Years: Medication Compliance 50%			NA	Small Denominator
12-18 Years: Medication Compliance 75%			NA	Small Denominator
19-50 Years: Medication Compliance 50%			NA	Small Denominator
19-50 Years: Medication Compliance 75%			NA	Small Denominator
51-64 Years: Medication Compliance 50%			NA	Small Denominator
51-64 Years: Medication Compliance 75%			NA	Small Denominator
Total: Medication Compliance 50%			NA	Small Denominator
Total: Medication Compliance 75%			NA	Small Denominator
Asthma Medication Ratio (amr)	Y			
5-11 Years			NA	Small Denominator
12-18 Years			NA	Small Denominator
19-50 Years			NA	Small Denominator
51-64 Years			NA	Small Denominator
Total			NA	Small Denominator
Effectiveness of Care: Cardiovascular Conditions				

Controlling High Blood Pressure (cbp)		38.2%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	25.0%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
<i>Received Statin Therapy: 21-75 Years (Male)</i>			NA	Small Denominator
<i>Statin Adherence 80%: 21-75 Years (Male)</i>			NA	Small Denominator
<i>Received Statin Therapy: 40-75 Years (Female)</i>			NA	Small Denominator
<i>Statin Adherence 80%: 40-75 Years (Female)</i>			NA	Small Denominator
<i>Received Statin Therapy: Total</i>			NA	Small Denominator
<i>Statin Adherence 80%: Total</i>			NA	Small Denominator
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
<i>Hemoglobin A1c (HbA1c) Testing</i>		76.9%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>		64.7%	R	Reportable
<i>HbA1c Control (<8.0%)</i>		29.9%	NQ	Not Required
<i>HbA1c Control (<7.0%)</i>		0.0%	NQ	Not Required
<i>Eye Exam (Retinal) Performed</i>		36.0%	R	Reportable
<i>Medical Attention for Nephropathy</i>		84.2%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>		46.2%	NQ	Not Required
Statin Therapy for Patients With Diabetes (spd)	Y			
<i>Received Statin Therapy</i>			NA	Small Denominator
<i>Statin Adherence 80%</i>			NA	Small Denominator
Effectiveness of Care: Behavioral Health				
Antidepressant Medication Management (amm)	Y			
<i>Effective Acute Phase Treatment</i>		45.3%	R	Reportable
<i>Effective Continuation Phase Treatment</i>		32.8%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			
<i>Initiation Phase</i>			NA	Small Denominator
<i>Continuation and Maintenance (C&M) Phase</i>			NA	Small Denominator
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
<i>6-17 years - 30-Day Follow-Up</i>		51.0%	R	Reportable
<i>6-17 years - 7-Day Follow-Up</i>		32.5%	R	Reportable
<i>18-64 years - 30-Day Follow-Up</i>		29.1%	R	Reportable
<i>18-64 years - 7-Day Follow-Up</i>		16.7%	R	Reportable
<i>65+ years - 30-Day Follow-Up</i>			NA	Small Denominator
<i>65+ years - 7-Day Follow-Up</i>			NA	Small Denominator
<i>Total - 30-Day Follow-Up</i>		35.1%	R	Reportable
<i>Total - 7-Day Follow-Up</i>		21.0%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
<i>6-17 years - 30-Day Follow-Up</i>		65.4%	R	Reportable
<i>6-17 years - 7-Day Follow-Up</i>		49.2%	R	Reportable
<i>18-64 years - 30-Day Follow-Up</i>		38.2%	R	Reportable
<i>18-64 years - 7-Day Follow-Up</i>		28.1%	R	Reportable
<i>65+ years - 30-Day Follow-Up</i>			NA	Small Denominator
<i>65+ years - 7-Day Follow-Up</i>			NA	Small Denominator
<i>Total - 30-Day Follow-Up</i>		45.6%	R	Reportable
<i>Total - 7-Day Follow-Up</i>		33.8%	R	Reportable
Follow-Up After High-Intensity Care for Substance Use Disorder (fui)	Y			
<i>13-17 years - 30-Day Follow-Up</i>			NA	Small Denominator
<i>13-17 years - 7-Day Follow-Up</i>			NA	Small Denominator
<i>18-64 years - 30-Day Follow-Up</i>		38.3%	R	Reportable
<i>18-64 years - 7-Day Follow-Up</i>		16.1%	R	Reportable
<i>65+ years - 30-Day Follow-Up</i>			NA	Small Denominator
<i>65+ years - 7-Day Follow-Up</i>			NA	Small Denominator
<i>Total - 30-Day Follow-Up</i>		37.2%	R	Reportable
<i>Total - 7-Day Follow-Up</i>		15.7%	R	Reportable
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)	Y			
<i>30-Day Follow-Up: 13-17 Years</i>		2.6%	R	Reportable
<i>7-Day Follow-Up: 13-17 Years</i>		2.6%	R	Reportable
<i>30-Day Follow-Up: 18+ Years</i>		15.9%	R	Reportable
<i>7-Day Follow-Up: 18+ Years</i>		9.2%	R	Reportable
<i>30-Day Follow-Up: Total</i>		15.3%	R	Reportable
<i>7-Day Follow-Up: Total</i>		8.9%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	70.8%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		63.1%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)			NA	Small Denominator
Pharmacotherapy for Opioid Use Disorder (pod)	Y			
<i>16-64 years</i>			R	Reportable

65+ years			R	Reportable
<i>Total</i>		19.9%	R	Reportable
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	47.4%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
<i>Blood glucose testing - 1-11 Years</i>		48.7%	R	Reportable
<i>Cholesterol Testing - 1-11 Years</i>		32.1%	R	Reportable
<i>Blood glucose and Cholesterol Testing - 1-11 Years</i>		29.5%	R	Reportable
<i>Blood glucose testing - 12-17 Years</i>		69.0%	R	Reportable
<i>Cholesterol Testing - 12-17 Years</i>		35.9%	R	Reportable
<i>Blood glucose and Cholesterol Testing - 12-17 Years</i>		33.8%	R	Reportable
<i>Blood glucose testing - Total</i>		61.9%	R	Reportable
<i>Cholesterol Testing - Total</i>		34.5%	R	Reportable
<i>Blood glucose and Cholesterol Testing - Total</i>		32.3%	R	Reportable
Effectiveness of Care: Overuse/Appropriateness				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		0.8%	R	Reportable
Appropriate Treatment for Upper Respiratory Infection (uri)	Y			
<i>3months-17 Years</i>		86.55%	R	Reportable
<i>18-64 Years</i>		69.07%	R	Reportable
<i>65+ Years</i>		0.0%	R	Reportable
<i>Total</i>		82.6%	R	Reportable
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (aab)	Y			
<i>3 months-17 Years</i>		44.5%	R	Reportable
<i>18-64 Years</i>		65.0%	R	Reportable
<i>65+ Years</i>			NA	Small Denominator
<i>Total</i>		48.2%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		74.0%	R	Reportable
Use of Opioids at High Dosage (hdo)	Y	1.9%	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
<i>Multiple Prescribers</i>		17.7%	R	Reportable
<i>Multiple Pharmacies</i>		4.6%	R	Reportable
<i>Multiple Prescribers and Multiple Pharmacies</i>		2.5%	R	Reportable
Risk of Continued Opioid Use (cou)	Y			
<i>18-64 years - >=15 Days covered</i>		1.4%	R	Reportable
<i>18-64 years - >=31 Days covered</i>		0.8%	R	Reportable
<i>65+ years - >=15 Days covered</i>			NA	Small Denominator
<i>65+ years - >=31 Days covered</i>			NA	Small Denominator
<i>Total - >=15 Days covered</i>		1.4%	R	Reportable
<i>Total - >=31 Days covered</i>		0.8%	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
<i>20-44 Years</i>		64.1%	R	Reportable
<i>45-64 Years</i>		70.0%	R	Reportable
<i>65+ Years</i>		77.2%	R	Reportable
<i>Total</i>		66.5%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
<i>12-24 Months</i>		94.2%	R	Reportable
<i>25 Months - 6 Years</i>		83.6%	R	Reportable
<i>7-11 Years</i>			NA	Small Denominator
<i>12-19 Years</i>			NA	Small Denominator
Annual Dental Visit (adv)	Y			
<i>2-3 Years</i>		63.2%	R	Reportable
<i>4-6 Years</i>	Y			
<i>7-10 Years</i>		42.7%	R	Reportable
<i>11-14 Years</i>		13.8%	R	Reportable
<i>15-18 Years</i>				
<i>19-20 Years</i>		70.8%	R	Reportable
<i>Total</i>		59.1%	R	Reportable
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	Y			
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		37.5%		
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>		12.5%		
<i>Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		0.0%		
<i>Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>		0.0%		
<i>Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		44.9%		

Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		13.5%		
Total: Initiation of AOD Treatment: 13-17 Years		41.1%		
Total: Engagement of AOD Treatment: 13-17 Years		13.4%		
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		37.3%		
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		12.3%		
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		59.5%		
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		25.6%		
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		40.9%		
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		10.5%		
Total: Initiation of AOD Treatment: 18+ Years		41.9%		
Total: Engagement of AOD Treatment: 18+ Years		14.5%		
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		37.3%		
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		12.3%		
Opioid abuse or dependence: Initiation of AOD Treatment: Total		59.5%		
Opioid abuse or dependence: Engagement of AOD Treatment: Total		25.6%		
Other drug abuse or dependence: Initiation of AOD Treatment: Total		41.3%		
Other drug abuse or dependence: Engagement of AOD Treatment: Total		10.8%		
Total: Initiation of AOD Treatment: Total		42.7%	R	Reportable
Total: Engagement of AOD Treatment: Total		13.8%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		70.8%	R	Reportable
Postpartum Care		59.1%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y			
1-11 Years		74.1%	R	Reportable
12-17 Years		44.7%	R	Reportable
Total		56.9%	R	Reportable
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits			NA	Small Denominator
1 Visit			NA	Small Denominator
2 Visits			NA	Small Denominator
3 Visits			NA	Small Denominator
4 Visits			NA	Small Denominator
5 Visits			NA	Small Denominator
6+ Visits			NA	Small Denominator
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		54.6%	R	Reportable
Adolescent Well-Care Visits (awc)		34.1%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NQ	Not Required
Ambulatory Care: Disabled (ambc)			NQ	Not Required
Ambulatory Care: Other (ambd)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NQ	Not Required
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NQ	Not Required
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NQ	Not Required
Mental Health Utilization: Disabled (mptc)	Y		NQ	Not Required
Mental Health Utilization: Other (mptd)	Y		NQ	Not Required
Antibiotic Utilization: Total (abxa)	Y		R	Reportable

Antibiotic Utilization: Dual Eligibles (abxb)	Y		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	Y		NQ	Not Required
Antibiotic Utilization: Other (abxd)	Y		NQ	Not Required
Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive Information				
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NQ	Not Required
Enrollment by Product Line: Disabled (enpc)			NQ	Not Required
Enrollment by Product Line: Other (enpd)			NQ	Not Required
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (tim)			R	Reportable
Measures Collected using Electronic Clinical Data Systems				
Follow-Up Care for Children Prescribed ADHD Medication (add-e)	Y			
<i>Initiation Phase</i>			NR	Not Reported
<i>Continuation and Maintenance Phase</i>			NR	Not Reported
Breast Cancer Screening (bcs-e)			NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9 - Time period 1: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 2: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 3: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Total: Total Total</i>			NR	Not Reported
Depression Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Positive Screen: Total Total</i>			NR	Not Reported
Adult Immunization Status (ais)				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Zoster: Total</i>			NR	Not Reported
<i>Composite: Total</i>			NR	Not Reported
Postpartum Depression Screening and Follow-Up (pds)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Depression Screening and Follow-Up (pnd)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Immunization Status (prs)				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Combination: Total</i>			NR	Not Reported